In an effort to help individuals gain access to breast health services, Barbells for Boobs and CancerCare®, the leading national cancer support organization, have officially launched the NYC Support Line.
In an effort to help individuals gain access to breast health services, Barbells for Boobs and CancerCare®, the leading national cancer support organization, have officially launched the NYC Support Line. This new breast health support line is the first responder to individuals with breast health concerns in the five boroughs of New York.
“Everyone has a right to know if they are living with breast cancer,” says Zionna Hanson, CEO of Barbells for Boobs, a nonprofit with a mission to help mobilize and empower people to take action in breast cancer. “In many states, there are rules and restrictions that prevent women from getting the free breast cancer screenings they need. We are dedicated to helping them overcome these barriers.”
The support line will direct individuals to services and screenings regardless of age, gender, income and insurance status. Those seeking assistance can call the NYC Support Line at 855-BFB-2DAY (855-232-2329) from 10:00 a.m. to 5:00 p.m. ET, Monday through Friday, to access local resources and navigation for:
“For nearly 75 years, CancerCare has provided free support services to cancer patients and we are excited to expand our services through this partnership,” said Patricia J. Goldsmith, CEO of CancerCare. “This new partnership will help individuals in New York City gain access to life-saving screenings.”
Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium
January 16th 2023Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.
FDA Approves Adjuvant Ribociclib Plus AI Therapy for HR+, HER2- Breast Cancer
September 17th 2024The Food and Drug Administration approved ribociclib plus an aromatase inhibitor for hormone receptor (HR)–positive, HER2-negative stage II and III early breast cancer that has a high risk of recurrence.